S1P1 Receptor Modulators for Relapsing MS
Bryan Walker, MHS, PA-C, describes the rationale for treating relapsing multiple sclerosis (MS) with sphingosine 1-phosphate (S1P1) receptor modulators and compares available options.
Clinical Experience Treating Relapsing MS With Cladribine
Best practices for treating patients with relapsing multiple sclerosis (MS) with cladribine, based on data revealed by clinical trials and experience in real-world practice.
Caring for Transgender and Gender-Diverse Patients With Migraine: Jennifer Hranilovich, MD
September 5th 2021Discussing the key takeaways for clinicians when it comes to treating this patient population, the assistant professor of pediatrics and neurology at the University of Colorado School of Medicine emphasized the need to improve communication.
AUPN Leadership Minute Episode 14: Challenges of Virtual Residency Interviews
September 3rd 2021Episode 14 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Nina Browner, MD, of University of North Carolina School of Medicine. [WATCH TIME: 5 minutes]
Risk of Relapse/Progression in MS
A discussion on the integration of newer therapies, like cladribine, into the treatment landscape for relapsing multiple sclerosis (MS), and insight regarding what is currently understood about risks of disease progression and relapse.
Cladribine Treatment for Relapsing MS
An overview of clinical trial data supporting the use of cladribine as treatment for relapsing multiple sclerosis (MS).
New AASM Guideline, Improved Awareness of Sleep Disorders: Lynn Marie Trotti, MD, MSc
September 2nd 2021The professor of neurology at Emory University School of Medicine spoke on the potential for the new AASM hypersomnolence guideline to educate providers treating patients with sleep disorders.
Innovative Alzheimer Prevention Research at IFN 2021: Richard Isaacson, MD
September 2nd 2021The director of the Alzheimer’s Prevention Clinic at Weill Cornell Medicine discussed the topics and ideas that clinicians should look forward to at the 2021 International Congress on the Future of Neurology.
COVID-19’s Potential Effect on Dementia Risk: James E. Galvin, MD, MPH
September 1st 2021The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the current understanding of COVID-19 and its associations with cognitive decline and Alzheimer disease.
New AASM Guideline for Treatment of Central Disorders of Hypersomnolence: Lynn Marie Trotti, MD
August 31st 2021The associate professor of neurology at Emory University School of Medicine provided an overview of the new guideline, which addresses narcolepsy, idiopathic hypersomnia, and Kleine-Levin syndrome.
Dementia Research in Multicultural Communities: James E. Galvin, MD, MPH
August 30th 2021The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed projects dedicated towards improving dementia recognition and care within multicultural communities.